- Home
- AVTX vs DOMH Comparison
AVTX vs DOMH Comparison
Compare AVTX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- DOMH
- Stock Information
- Founded
- AVTX 2011
- DOMH 1967
- Country
- AVTX United States
- DOMH United States
- Employees
- AVTX N/A
- DOMH N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- DOMH Health Care
- Exchange
- AVTX Nasdaq
- DOMH Nasdaq
- Market Cap
- AVTX 90.9M
- DOMH 11.6M
- IPO Year
- AVTX 2015
- DOMH N/A
- Fundamental
- Price
- AVTX $9.47
- DOMH $1.93
- Analyst Decision
- AVTX Buy
- DOMH
- Analyst Count
- AVTX 1
- DOMH 0
- Target Price
- AVTX $35.00
- DOMH N/A
- AVG Volume (30 Days)
- AVTX 13.2K
- DOMH 14.8K
- Earning Date
- AVTX 11-07-2024
- DOMH 11-04-2024
- Dividend Yield
- AVTX N/A
- DOMH N/A
- EPS Growth
- AVTX N/A
- DOMH N/A
- EPS
- AVTX N/A
- DOMH N/A
- Revenue
- AVTX $807,000.00
- DOMH $9,509,000.00
- Revenue This Year
- AVTX N/A
- DOMH N/A
- Revenue Next Year
- AVTX N/A
- DOMH N/A
- P/E Ratio
- AVTX N/A
- DOMH N/A
- Revenue Growth
- AVTX N/A
- DOMH 13292.96
- 52 Week Low
- AVTX $3.95
- DOMH $1.50
- 52 Week High
- AVTX $45.12
- DOMH $3.20
- Technical
- Relative Strength Index (RSI)
- AVTX 51.19
- DOMH 56.82
- Support Level
- AVTX $8.49
- DOMH $1.81
- Resistance Level
- AVTX $10.20
- DOMH $1.95
- Average True Range (ATR)
- AVTX 0.66
- DOMH 0.13
- MACD
- AVTX 0.11
- DOMH -0.01
- Stochastic Oscillator
- AVTX 60.75
- DOMH 34.05
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.